Find a Research Expert

Experts
 Menu

Mark Lawler

Institution

Trinity College Dublin

Contact

Subjects

Biochemistry

Microbiology

Details
Publications 38
As first author 6
As last author 10
Unique topics 339
Collaborations 71
Sources 6
Are you Mark Lawler? Click here to provide feedback on your profile.
All
2017
2016
2012
2011
2010
2009
2008
2007
2006
Earlier
All
2017
2016
2012
2011
2010
2009
2008
2007
2006
Earlier

2017

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.
2016

A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer.
2012

IGFBP7 promoter methylation and gene expression analysis in prostate cancer.
2011

Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.
2011

The role of secreted frizzled-related protein 2 expression in prostate cancer.
2010

BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.
2010

DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data.
2010

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
2010

Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines.
2010

MAD2 downregulation in hypoxia is independent of promoter hypermethylation.
2010

Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro.
2010

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.
2009

4-Amino-1,8-naphthalimide-based Tröger's bases as high affinity DNA targeting fluorescent supramolecular scaffolds.
2009

DNA mismatch repair and the transition to hormone independence in breast and prostate cancer.
2009

Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity.
2009

Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT.
2009

The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers.
2009

The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
2008

Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro.
2008

Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
2008

The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.
2008

The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?
2007

A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin.
2007

Hypoxia in prostate cancer: a powerful shield against tumour destruction?
2007

In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.
2007

Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma.
2006

The emerging roles of DNA methylation in the clinical management of prostate cancer.
2001

Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia.
2001

Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents.
2000

Prevalence of the prothrombin G20210A mutation in the Irish populations: use of a novel polymerase chain reaction approach.
2000

Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease.
1999

Molecular Medicine and Molecular Pathology for Haematologists: I. Gene Speak made Easy: An Overview of Genes and Gene Expression.
1999

Molecular Medicine and Molecular Pathology for Hematologists: II. Lets go Techno; Principles of the Molecular Technologies and their Applications in Haematology.
1996

D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity.
1994

Adenovirus 12 E1A gene detection by polymerase chain reaction in both the normal and coeliac duodenum.
1990

Autosomal dominant retinitis pigmentosa: linkage to rhodopsin and evidence for genetic heterogeneity.
1989

Autosomal dominant retinitis pigmentosa (ADRP): localization of an ADRP gene to the long arm of chromosome 3.
1989

Chimaerism following allogeneic bone marrow transplantation: detection of residual host cells using the polymerase chain reaction.

These arethe6 unique sources for Mark Lawler's 38 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Royal College of Surgeons in Ireland 3
Ireland -> Royal College of Surgeons in Ireland -> PubMed 2
Ireland -> Trinity College Dublin 33
Ireland -> Trinity College Dublin -> PubMed 30
Ireland -> University College Dublin 2
Ireland -> University College Dublin -> PubMed 2

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.